Actelion Ltd., Switzerland's largest biotechnology company, which moved an experimental drug Pivlaz aimed at reducing blood vessel spasms into late-stage clinical testing will make a 15 million Swiss franc ($13.3 million) milestone payment to former shareholders of the medicine's developer, Axovan, which Actelion acquired in 2003.
[Click here for full story at: BLOOMBERG.COM]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment